Engineered immune cells with nanomaterials to improve adoptive cell therapy

Area of Science:

• Immunology
• Biotechnology
• Nanotechnology

Background:

• Conventional cell-based cancer immunotherapy using T cells and dendritic cell (DC) vaccines has limitations.
• These limitations include low success rates and off-target side effects.
• Therapeutic cells face environmental and inherent challenges impacting efficacy.

Purpose of the Study:

• To explore nanoengineering strategies for enhancing cell-based cancer immunotherapy.
• To overcome the limitations of traditional adoptive cell therapy and DC vaccines.
• To improve the efficacy of infused therapeutic cells in combating cancer.

Main Methods:

• Engineering of immune cells including T cells, NK cells, DCs, and macrophages.
• Application of nanoengineering principles to modify therapeutic cells.
• Focus on enhancing anti-tumoral phenotypes, tumor targeting, and cell viability.

Main Results:

• Nanoengineering improves the ability of infused cells to maintain anti-tumoral functions.
• Engineered cells demonstrate enhanced tumor targeting capabilities.
• Improved innate functionalities and viability of therapeutic cells are achieved.

Conclusions:

• Nanoengineering represents a promising advancement in cell-based cancer immunotherapy.
• This approach effectively addresses limitations of conventional cell therapies.
• Enhanced cell therapies hold potential for improved cancer treatment outcomes.